MA39909A - Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer - Google Patents

Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer

Info

Publication number
MA39909A
MA39909A MA039909A MA39909A MA39909A MA 39909 A MA39909 A MA 39909A MA 039909 A MA039909 A MA 039909A MA 39909 A MA39909 A MA 39909A MA 39909 A MA39909 A MA 39909A
Authority
MA
Morocco
Prior art keywords
antibody
drug
conjugate
igf
treatment
Prior art date
Application number
MA039909A
Other languages
English (en)
Other versions
MA39909B1 (fr
Inventor
Charlotte Beau-Larvor
Matthieu Broussas
Thierry Champion
Liliane Goetsch
Jean-François Haeuw
Michel Perez
Ian Rilatt
Alain Robert
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA39909A publication Critical patent/MA39909A/fr
Publication of MA39909B1 publication Critical patent/MA39909B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un conjugué anticorps-médicament pouvant se lier à l'igf-1r. Selon un aspect, l'invention concerne un conjugué anticorps-médicament comprenant un anticorps pouvant se lier à l'igf-1r, ledit anticorps étant conjugué à au moins un médicament choisi parmi des dérivés de la dolastatine 10 et des auristatines. L'invention concerne également une méthode de traitement et l'utilisation dudit conjugué anticorps-médicament pour le traitement du cancer.
MA39909A 2014-04-25 2015-04-27 Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer MA39909B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305620 2014-04-25
PCT/EP2015/059045 WO2015162291A1 (fr) 2014-04-25 2015-04-27 Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
EP15720045.2A EP3134124B1 (fr) 2014-04-25 2015-04-27 Conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA39909A true MA39909A (fr) 2017-03-01
MA39909B1 MA39909B1 (fr) 2019-05-31

Family

ID=50630736

Family Applications (2)

Application Number Title Priority Date Filing Date
MA047811A MA47811A (fr) 2014-04-25 2015-04-27 Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer
MA39909A MA39909B1 (fr) 2014-04-25 2015-04-27 Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA047811A MA47811A (fr) 2014-04-25 2015-04-27 Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer

Country Status (27)

Country Link
US (2) US10633448B2 (fr)
EP (2) EP3134124B1 (fr)
JP (1) JP6258523B2 (fr)
KR (1) KR101795984B1 (fr)
CN (1) CN106456800B (fr)
AU (1) AU2015250759B2 (fr)
BR (1) BR112016024619A2 (fr)
CA (1) CA2946469C (fr)
CY (1) CY1121783T1 (fr)
DK (1) DK3134124T3 (fr)
ES (1) ES2727103T3 (fr)
HR (1) HRP20190888T8 (fr)
HU (1) HUE044862T2 (fr)
IL (1) IL248455B (fr)
LT (1) LT3134124T (fr)
MA (2) MA47811A (fr)
MX (1) MX2016013704A (fr)
MY (1) MY186711A (fr)
PL (1) PL3134124T3 (fr)
PT (1) PT3134124T (fr)
RS (1) RS58742B1 (fr)
RU (1) RU2692563C2 (fr)
SA (1) SA516380120B1 (fr)
SI (1) SI3134124T1 (fr)
TN (1) TN2016000472A1 (fr)
UA (1) UA120364C2 (fr)
WO (1) WO2015162291A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3134124T1 (sl) * 2014-04-25 2019-06-28 Pierre Fabre Medicament Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
AU2016344663B2 (en) 2015-10-26 2023-09-07 Pierre Fabre Medicament Composition for the treatment of IGF-1R expressing cancer
US11340233B2 (en) * 2016-03-07 2022-05-24 Pierre Fabre Medicament Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
US12011485B2 (en) 2018-09-27 2024-06-18 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
CN111327570B (zh) 2018-12-14 2021-09-17 北京京东尚科信息技术有限公司 验证方法、装置和计算机可读存储介质
EP3735991A1 (fr) 2019-05-06 2020-11-11 Pierre Fabre Medicament Adc pour un traitement concomitant ou postérieur au docétaxel
EP3909612A1 (fr) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition de nanoparticules
WO2023240223A2 (fr) * 2022-06-10 2023-12-14 Acelyrin, Inc. Compositions d'anticorps anti-igf-1r
EP4353220A1 (fr) 2022-10-12 2024-04-17 Pierre Fabre Medicament Utilisation d'une composition aqueuse liquide pour la solubilisation et la stabilisation d'un conjugué anticorps-médicament

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2233928T3 (es) 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. Derivados de dolastatina.
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
KR101200133B1 (ko) * 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
CA2580141C (fr) 2004-09-23 2013-12-10 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
TW200833711A (en) 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
PE20090190A1 (es) 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
AU2008251608B2 (en) 2007-05-08 2014-03-27 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
ES2588194T3 (es) 2008-04-11 2016-10-31 Seattle Genetics, Inc. Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
RU2011140491A (ru) 2009-03-06 2013-04-20 Эдженсис, Инк. Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12
US20100316639A1 (en) * 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
US8722629B2 (en) 2010-06-10 2014-05-13 Seattle Genetics, Inc. Auristatin derivatives and use thereof
ES2553874T3 (es) 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
US9272052B2 (en) * 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
WO2012059882A2 (fr) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Conjugués de polypeptides obtenus par génie biologique, et procédé de fabrication correspondants au moyen de transglutaminase
EP2686336B1 (fr) 2011-03-16 2015-05-06 Seattle Genetics, Inc. N-carboxyalkyl-auristatines et leur utilisation
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
WO2012166559A1 (fr) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel
CA2837586C (fr) 2011-05-27 2018-12-11 Ambrx, Inc. Compositions contenant des derives de dolastatine lies a des acides amines non naturel
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2858676B1 (fr) 2012-06-07 2019-03-13 Ambrx, Inc. Conjugués anticorps-médicament d'antigène membranaire spécifique à la prostate
KR102190832B1 (ko) 2012-06-19 2020-12-15 암브룩스, 인코포레이티드 항cd70 항체 약물 컨쥬게이트
WO2014008375A1 (fr) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Polymères modifiés en extrémité et leurs conjugués
US20160106856A1 (en) 2012-08-14 2016-04-21 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
US20150314007A1 (en) 2012-12-21 2015-11-05 Glykos Finland Oy Linker-payload molecule conjugates
FR3005051A1 (fr) 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
SI3134124T1 (sl) * 2014-04-25 2019-06-28 Pierre Fabre Medicament Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
JP6835591B2 (ja) * 2014-04-25 2021-02-24 ピエール、ファーブル、メディカマン Ｉｇｆ−１ｒ抗体および癌処置のためのアドレッシングビヒクルとしてのその使用
RU2685259C2 (ru) 2014-04-25 2019-04-17 Пьер Фабр Медикамент Конъюгат антитела и лекарственного средства и его применение для лечения рака
AU2016344663B2 (en) * 2015-10-26 2023-09-07 Pierre Fabre Medicament Composition for the treatment of IGF-1R expressing cancer

Also Published As

Publication number Publication date
KR20160146817A (ko) 2016-12-21
LT3134124T (lt) 2019-05-27
DK3134124T3 (da) 2019-05-06
EP3134124B1 (fr) 2019-02-20
MY186711A (en) 2021-08-12
RU2016145444A (ru) 2018-05-28
EP3134124A1 (fr) 2017-03-01
CN106456800B (zh) 2018-05-01
HUE044862T2 (hu) 2019-11-28
RS58742B1 (sr) 2019-06-28
ES2727103T8 (es) 2020-03-02
PT3134124T (pt) 2019-06-03
AU2015250759B2 (en) 2017-11-30
ES2727103T3 (es) 2019-10-14
WO2015162291A1 (fr) 2015-10-29
IL248455A0 (en) 2016-11-30
TN2016000472A1 (en) 2018-04-04
RU2692563C2 (ru) 2019-06-25
EP3498301A1 (fr) 2019-06-19
HRP20190888T8 (hr) 2019-10-04
SA516380120B1 (ar) 2019-02-27
UA120364C2 (uk) 2019-11-25
AU2015250759A1 (en) 2016-11-10
KR101795984B1 (ko) 2017-11-10
MA47811A (fr) 2019-06-19
PL3134124T3 (pl) 2019-09-30
JP2017513900A (ja) 2017-06-01
MX2016013704A (es) 2017-03-31
US20200270352A1 (en) 2020-08-27
SI3134124T1 (sl) 2019-06-28
US20170043031A1 (en) 2017-02-16
CA2946469A1 (fr) 2015-10-29
RU2016145444A3 (fr) 2018-11-22
HRP20190888T1 (hr) 2019-07-12
MA39909B1 (fr) 2019-05-31
CA2946469C (fr) 2019-10-29
JP6258523B2 (ja) 2018-01-10
IL248455B (en) 2020-01-30
US11661457B2 (en) 2023-05-30
BR112016024619A2 (pt) 2017-10-10
CN106456800A (zh) 2017-02-22
US10633448B2 (en) 2020-04-28
CY1121783T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
MX2016013999A (es) Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
PH12016501411A1 (en) Bifunctional cytotoxic agents
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
NZ738008A (en) Tigit-binding agents and uses thereof
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
EP3600302A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3710039A4 (fr) Méthodes et compositions de traitement du cancer par ciblage de la voie clec2d-klrb1
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3585398A4 (fr) Compositions et méthodes pour le traitement du cancer
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
EP3699199A4 (fr) Anticorps anti-msln et composition pharmaceutique destinée au traitement du cancer, contenant ledit anticorps
EP3570837A4 (fr) Compositions et procédés pour le traitement d'un cancer indépendant des androgènes
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
EP3703653A4 (fr) Compositions et méthodes pour le traitement de cancers
WO2015175599A3 (fr) Immunothérapie à l'aide d'agents de liaison
EP3441465A4 (fr) Composition médicamenteuse pour traitement du cancer mettant en oeuvre un anticorps anti-mct5